Company profile
PLIANT THERAPEUTICS, INC.
NASDAQ:PLRXBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| Bexotegrast | phase2 | — | 6 | completed, terminated |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (7)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06270706 | phase1 | recruiting | 2023-08-30 | 2030-06-01 | Pliant Therapeutics, Inc. | A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors |
| NCT04396756 | phase2 | completed | 2020-03-03 | 2023-02-01 | Pliant Therapeutics, Inc. | Evaluation of Efficacy and Safety of PLN-74809 in Patients With Idiopathic Pulmonary Fibrosis |
| NCT04565249 | phase2 | terminated | 2020-10-22 | 2021-06-01 | Pliant Therapeutics, Inc. | Evaluation of the Safety, Tolerability, and Pharmacokinetics of PLN-74809 in Participants With Acute Respiratory Distress Syndrome (ARDS) Associated With at Least Severe COVID-19 |
| NCT05621252 | phase2 | completed | 2022-07-13 | 2023-12-27 | Pliant Therapeutics, Inc. | Imaging Evaluation of PLN-74809 in Participants With IPF (PLN-74809) |
| NCT04072315 | phase2 | completed | 2020-02-13 | 2022-06-27 | Pliant Therapeutics, Inc. | Phase 2a Evaluation of PLN-74809 on αvβ6 Receptor Occupancy Using PET Imaging in Participants With IPF/ |
FDA applications (0)
No records yet.